COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5microg...
| ID | 40872011000001104 |
|---|---|
| Concept | Generic COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials |
| Name | COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials |
| Abbreviated name | COVID-19 Vacc VidPrevtyn (B.1.351) 0.5ml inj multidose vials |
| Description | COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi Pasteur) |
| Date of name applicability | 10 Jan 2023 |
| Previous Name | COVID-19 Vaccine Sanofi (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose emulsion for injection multidose vials |
| Supplier | Sanofi Pasteur |
| Licensed as | Medicines - MHRA/EMA |
| Previously licensed as | None |
| License change reason | Licence Granted |
| Date of change of licensing authority | 10 Jan 2023 |
| EMA (European Medicines Agency) Monitoring | 1 |
| Restrictions on availability | Restricted Availability |
| Licensed route | Intramuscular |